Work

A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2555

Authors: Neeraj Gupta, Karthik Venkatakrishnan, Dennis A Noe, Michael J Hanley, Jiang Yu, Alberto Bessudo, Sunil Sharma, Robert Matthew Strother, Yaping Shou, John J. Nemunaitis

Institutions: Takeda Oncology (United States), California Cancer Associates for Research and Excellence, University of Utah, Indiana University Indianapolis, Mary Crowley Cancer Research Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603433800

Cites:

Cited by: 4

Related to: 10